buprenorphine and naloxone

DRUG3 trials

Sponsors

National Institute on Drug Abuse (NIDA), BioDelivery Sciences International, Indivior Inc.

Conditions

Opioid DependenceOpioid Use DisorderOpioid-Related Disorders

Phase 2

Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

CompletedNCT02044094

Indivior Inc.Opioid Use Disorder

Start: 2013-11-30End: 2014-07-31Updated: 2018-04-24

Phase 3

Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects

WithdrawnNCT01713803

BioDelivery Sciences InternationalOpioid Dependence

End: 2017-05-01Updated: 2017-05-04

Unknown Phase

Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users

CompletedNCT00158236

National Institute on Drug Abuse (NIDA)Opioid-Related Disorders

Start: 1997-01-31End: 1998-03-31Target: 7Updated: 2017-01-12

Related Papers

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder

Frontiers in Pharmacology2022-11-1826 citations